Has Jonathan Feistmann, MD received payments from drug or device companies?

Yes. Drug and device makers reported $45,617 in general payments to Jonathan Feistmann, MD across 113 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Feistmann, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Feistmann, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Feistmann, MD

Ophthalmology · New York, NYNPI 1447331087

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,723 of the $45,617 with a category attached, or 67.4%. Carl Zeiss Meditec, Inc. accounts for 72.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $21,255 and has fallen 57.5% since, to $9,027 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,617in general payments, 2019–2025

Across 113 payments — averaging $403.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Carl Zeiss Meditec, Inc.$33K
Carl Zeiss Meditec USA, Inc.$5K
Alcon$2K
Apellis Pharmaceuticals, Inc.$2K
Regeneron Healthcare Solutions, Inc.$2K
Onmark, Inc.$1K
plus $589 from 9 others

$4,650in research payments, 2019–2025

Across 3 payments — averaging $1550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Alcon Research LLC$5K

What the payments were for

Consulting fees$30,72367%
Speaking & faculty fees$5,75013%
Travel & lodging$2,3065%
Food & beverage$3,5198%
Gifts$190%
Entertainment$340%
Other$3,2657%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Carl Zeiss Meditec, Inc.	12	$32,980
Carl Zeiss Meditec USA, Inc.	6	$4,853
Alcon	9	$2,368
Apellis Pharmaceuticals, Inc.	7	$1,816
Regeneron Healthcare Solutions, Inc.	53	$1,571
Onmark, Inc.	9	$1,440
Mallinckrodt Hospital Products Inc.	3	$251
Astellas Pharma US Inc	3	$95
Genentech USA, Inc.	3	$72
Eyepoint US, Inc.	2	$45
Optos, Inc.	2	$34
Regeneron	1	$34
Bausch & Lomb Americas Inc.	1	$20
Carl Zeiss Meditec AG	1	$19
US Oncology Corporate, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,617 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024

$3,817,756

Medicare patients

722

Services billed

55,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ProlensaBromfenac Sodium	37	$15,893
Bromfenac Sodium	48	$6,320
Prednisolone Acetate	98	$5,265
Difluprednate	22	$1,329
Ofloxacin	39	$800
Latanoprost	116	$674
Ketorolac Tromethamine	24	$503
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	34	$411
Dorzolamide Hcl	23	$311
Brimonidine Tartrate	24	$240
Timolol Maleate	16	$172

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

Nathan RadcliffeNew York$2.1M
Richard SpaideNew York$1.7M
Joshua YoungNew York$814K
Joseph PanarelliNew York$541K
Eric RosenbergNew York$434K
Michael CooneyNew York$398K
David GuyerNew York$322K
Ashley BrissetteNew York$315K
Jason SlakterNew York$272K
David ChuNew York$234K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →